362 related articles for article (PubMed ID: 34585512)
21. CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.
Pettitt D; Arshad Z; Smith J; Stanic T; Holländer G; Brindley D
Mol Ther; 2018 Feb; 26(2):342-353. PubMed ID: 29248427
[TBL] [Abstract][Full Text] [Related]
22. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
Cummins KD; Gill S
Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
[TBL] [Abstract][Full Text] [Related]
23. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Yu YD; Kim TJ
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
[TBL] [Abstract][Full Text] [Related]
25. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
26. Immunobiology of chimeric antigen receptor T cells and novel designs.
Walsh Z; Yang Y; Kohler ME
Immunol Rev; 2019 Jul; 290(1):100-113. PubMed ID: 31355496
[TBL] [Abstract][Full Text] [Related]
27. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
28. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
29. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Badar T; Shah NN
Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828
[TBL] [Abstract][Full Text] [Related]
31. T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Chandran SS; Klebanoff CA
Immunol Rev; 2019 Jul; 290(1):127-147. PubMed ID: 31355495
[TBL] [Abstract][Full Text] [Related]
32. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
[TBL] [Abstract][Full Text] [Related]
33. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
35. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
36. Multi-Specific CAR Targeting to Prevent Antigen Escape.
Walsh Z; Ross S; Fry TJ
Curr Hematol Malig Rep; 2019 Oct; 14(5):451-459. PubMed ID: 31332617
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
38. Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.
Zhang Z; Miao L; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():718686. PubMed ID: 34386015
[TBL] [Abstract][Full Text] [Related]
39. Driving the CAR to the Bone Marrow Transplant Program.
Dave H; Jerkins L; Hanley PJ; Bollard CM; Jacobsohn D
Curr Hematol Malig Rep; 2019 Dec; 14(6):561-569. PubMed ID: 31643018
[TBL] [Abstract][Full Text] [Related]
40. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]